Mechelen, Belgium - On 7 April 2020, Biocartis Group NV (the 'Company' or 'Biocartis'), an innovative molecular diagnostics company (Euronext Brussels: BCART), published its convening notice for the annual and extraordinary shareholders' meetings of the Company that will be held on 8 May 2020. On 9 April 2020, the Belgian Royal Decree no. 4 containing various provisions regarding co-ownership and the law on companies and associations in the framework of the fight against the Covid-19 pandemic was published.

Using the possibility offered by the aforementioned Royal Decree no. 4, and in order to protect the health of individual securities holders and the employees of the Company and others who are responsible for organizing the shareholders' meetings, the Board of Directors of the Company has decided to hold the annual and extraordinary shareholders' meetings behind closed doors without physical presence of the holders of securities of the Company, their proxyholders or others who have the right to attend the shareholders' meetings. This entails that:

The shareholders of the Company can exercise their voting rights only by way of a vote by mail or by proxy to the Chairman of the Board of Directors. Shareholders must provide their signed vote by mail form or proxy form to the Company at the latest on the fourth calendar day prior to the annual and extraordinary shareholders' meetings, i.e. on or before Monday 4 May 2020 at the latest.

Holders of securities of the Company can only exercise their right to ask questions related to the items on the agenda of the general shareholders' meetings in writing. These written questions must be provided to the Company at the latest on the fourth calendar day prior to the annual and extraordinary shareholders' meetings, i.e. on or before Monday 4 May 2020 at the latest. Written questions will be answered in writing and these answers will be published on the website of the Company, in accordance with applicable law.

The modalities of the aforementioned ways to participate in the annual and extraordinary shareholders' meetings are set out in the revised convening notice and relevant forms to vote by mail or by proxy. These documents can be consulted on the Company's website.

The Board of Directors would like to thank the securities holders for their understanding and cooperation.

--- END ---

More information:

Renate Degrave

Head of Corporate Communications & Investor Relations Biocartis

e-mail rdegrave@biocartis.com

tel +32 15 631 729

mobile +32 471 53 60 64

(C) 2020 Electronic News Publishing, source ENP Newswire